Intermediate affinity binding

TheraCIM® binds to EGFR with intermediate affinity (108 and 109 M) causing high tumour uptake and low uptake in normal tissue. This results in effective EGFR blockade without causing deleterious effects on the skin, because the optimal dose is far lower than the toxic dose.

Theracim Mechanism


Anti Cancer properties of TheraCIM®:

Antiproliferative activity

Antiangiogenic activity

Pro-apoptotic activity

Mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) activity

Radiosensitizing activity


Learn about the proposed mechanism of TheraCIM®